CC
Catalio Capital Management, LP
13F filer · CIK 0001958125Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$532MU.S. long equity reported on 13F
Positions3910 new · 12 closed
Net flow last quarter-$48.7MBuys minus sells
Top 10 positions weight56.7%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202639 positions | |||||
| $55.2M | 10.37% | 3.78% | New | Q2 2026 | |
| $35.3M | 6.63% | 0.01% | Not reported | Q4 2025 | |
| $34M | 6.39% | 0.02% | +64.3% | Q2 2025 | |
| $33.9M | 6.37% | 0.23% | +5.3% | Q4 2024 | |
| $26.6M | 4.99% | 1.36% | +16.5% | Q1 2025 | |
| $26.5M | 4.97% | 0.42% | -45.8% | Q1 2026 | |
| $23.8M | 4.47% | 0.02% | -1.9% | Q4 2024 | |
| $22.6M | 4.24% | 0.68% | New | Q2 2026 | |
| $22.3M | 4.19% | 0.06% | +15.9% | Q2 2025 | |
| $21.7M | 4.08% | 0.10% | +5.2% | Q1 2026 | |
| $18M | 3.37% | 1.17% | +82.1% | Q4 2024 | |
| $17.5M | 3.29% | 0.73% | +47.8% | Q4 2025 | |
| $17.1M | 3.21% | 0.67% | +44.5% | Q4 2025 | |
| $16.1M | 3.03% | 1.28% | +21.2% | Q1 2026 | |
| $14.8M | 2.79% | 0.13% | +8.3% | Q4 2024 | |
| $13.1M | 2.46% | 0.17% | New | Q2 2026 | |
| $11.7M | 2.19% | 0.42% | +29.6% | Q4 2024 | |
| $11.3M | 2.12% | 0.02% | -13.7% | Q4 2024 | |
| $10.6M | 1.99% | 0.08% | New | Q2 2026 | |
| $10.6M | 1.98% | 0.32% | -62.8% | Q2 2025 | |
| $10.3M | 1.94% | 0.36% | New | Q2 2026 | |
| $9.19M | 1.73% | 4.15% | +4.8% | Q4 2024 | |
| $8.57M | 1.61% | 0.96% | New | Q2 2026 | |
| $8.47M | 1.59% | 0.05% | -75.4% | Q4 2024 | |
| $7.45M | 1.40% | 0.33% | New | Q2 2026 | |
| $6.68M | 1.26% | 2.10% | +3.4% | Q3 2025 | |
| $6.27M | 1.18% | 0.85% | New | Q2 2026 | |
| $5.64M | 1.06% | 0.11% | -73.6% | Q1 2026 | |
| $5.44M | 1.02% | 0.15% | -13.4% | Q4 2025 | |
| $4.9M | 0.92% | 3.89% | +12.3% | Q4 2024 | |
| $4.7M | 0.88% | 0.29% | +75.5% | Q1 2026 | |
| $3.21M | 0.60% | 0.06% | -94.1% | Q4 2024 | |
| $2.43M | 0.46% | 0.40% | Not reported | Q4 2025 | |
| $1.99M | 0.37% | 0.88% | -10.3% | Q4 2024 | |
| $1.78M | 0.33% | Not reported | Not reported | Q4 2024 | |
| AATAIAtaiBeckley Inc. | $1.04M | 0.19% | 0.05% | Not reported | Q1 2026 |
| $630K | 0.12% | 1.40% | Not reported | Q4 2024 | |
| $511K | 0.10% | 0.63% | Not reported | Q1 2025 | |
| $368K | 0.07% | 0.06% | Not reported | Q2 2025 | |
| Q1 2026Reported May 15, 202641 positions | |||||
| $47M | 9.82% | 1.03% | -14.3% | Q4 2024 | |
| $32.1M | 6.70% | 0.22% | Not reported | Q4 2024 | |
| $29.5M | 6.17% | 0.21% | +8.3% | Q4 2024 | |
| $25.5M | 5.33% | 0.02% | -35.1% | Q4 2024 | |
| $24.4M | 5.09% | 1.18% | -12.8% | Q1 2025 | |
| $22.8M | 4.77% | 0.01% | -43.4% | Q2 2025 | |
| TPTERNTerns Pharmaceuticals, Inc. | $21.6M | 4.50% | 0.35% | +198.7% | Q4 2025 |
| $19.6M | 4.10% | 1.00% | New | Q1 2026 | |
| STSLNOSoleno Therapeutics Inc | $19.3M | 4.04% | 1.12% | +60.4% | Q1 2025 |
| $18.8M | 3.92% | 0.02% | -17.0% | Q4 2024 | |
| $17.8M | 3.72% | 0.87% | +423.4% | Q2 2025 | |
| $17.1M | 3.58% | 0.09% | New | Q1 2026 | |
| $14.2M | 2.97% | 0.18% | -16.6% | Q4 2024 | |
| $14.2M | 2.96% | 0.05% | +13.9% | Q2 2025 | |
| $13M | 2.73% | 1.06% | New | Q1 2026 | |
| $12.3M | 2.57% | 0.12% | +1.0% | Q4 2024 | |
| $11.9M | 2.48% | 0.53% | +32.3% | Q4 2025 | |
| $11.6M | 2.42% | 0.03% | -22.7% | Q4 2024 | |
| $11M | 2.29% | 0.46% | New | Q1 2026 | |
| $10M | 2.10% | 0.45% | -12.0% | Q1 2025 | |
| $9.82M | 2.05% | 0.47% | +254.5% | Q4 2025 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $8.59M | 1.79% | 0.83% | New | Q1 2026 |
| $8.03M | 1.68% | 0.78% | +70.3% | Q4 2024 | |
| $7.86M | 1.64% | 0.32% | +11.4% | Q4 2024 | |
| $7.07M | 1.48% | 0.66% | Not reported | Q4 2024 | |
| $5.25M | 1.10% | 0.06% | -52.1% | Q3 2025 | |
| $5.13M | 1.07% | 0.17% | -45.6% | Q4 2025 | |
| $5.05M | 1.06% | 2.16% | +30.2% | Q3 2025 | |
| $5M | 1.04% | 3.98% | +527.8% | Q4 2024 | |
| $3.21M | 0.67% | 0.11% | -75.9% | Q3 2025 | |
| $3.02M | 0.63% | 1.05% | -59.9% | Q4 2024 | |
| $2.75M | 0.58% | 0.31% | -64.6% | Q2 2025 | |
| $2.67M | 0.56% | 0.07% | New | Q1 2026 | |
| $2.58M | 0.54% | 0.11% | New | Q1 2026 | |
| $2.54M | 0.53% | 0.17% | New | Q1 2026 | |
| $2.51M | 0.53% | 3.46% | Not reported | Q4 2024 | |
| $1.43M | 0.30% | Not reported | Not reported | Q4 2024 | |
| $709K | 0.15% | 1.41% | Not reported | Q4 2024 | |
| AATAIAtaiBeckley Inc. | $697K | 0.15% | 0.05% | New | Q1 2026 |
| $464K | 0.10% | 1.10% | Not reported | Q2 2025 | |
| $454K | 0.09% | 0.64% | Not reported | Q1 2025 | |
| Q4 2025Reported Feb 17, 202644 positions | |||||
| $35.5M | 6.28% | 0.02% | Not reported | Q2 2025 | |
| $34.9M | 6.18% | 0.03% | Not reported | Q4 2024 | |
| $34.4M | 6.07% | 0.02% | +37.1% | Q4 2024 | |
| $31.4M | 5.55% | 0.51% | New | Q4 2025 | |
| $27.9M | 4.92% | 0.00% | -54.8% | Q1 2025 | |
| $26.9M | 4.76% | 1.51% | -2.1% | Q4 2024 | |
| $25.4M | 4.49% | 0.19% | -17.7% | Q4 2024 | |
| $25.1M | 4.44% | 1.37% | -25.9% | Q1 2025 | |
| $25M | 4.42% | 0.01% | New | Q4 2025 | |
| $23M | 4.07% | 0.03% | -15.7% | Q1 2025 | |
| $17.6M | 3.11% | 0.12% | -61.2% | Q4 2024 | |
| STSLNOSoleno Therapeutics Inc | $16.7M | 2.95% | 0.69% | -13.8% | Q1 2025 |
| $16.4M | 2.90% | 0.21% | -42.8% | Q4 2024 | |
| $15.9M | 2.82% | 0.03% | Not reported | Q4 2024 | |
| $15.4M | 2.72% | 0.01% | -61.9% | Q4 2024 | |
| $14.3M | 2.52% | 0.04% | -58.0% | Q2 2025 | |
| $13.3M | 2.36% | 0.53% | -7.2% | Q1 2025 | |
| $13.3M | 2.35% | 0.13% | -39.2% | Q3 2025 | |
| $12.8M | 2.26% | 0.45% | -10.3% | Q3 2025 | |
| $12.1M | 2.14% | 3.58% | +5.3% | Q4 2024 | |
| $12M | 2.13% | 0.41% | New | Q4 2025 | |
| $11.6M | 2.05% | 0.98% | -38.1% | Q2 2025 | |
| $10.3M | 1.82% | 0.24% | -17.5% | Q4 2024 | |
| AACLXArcellx, Inc. | $10.2M | 1.80% | 0.27% | New | Q4 2025 |
| $10.2M | 1.80% | 0.32% | New | Q4 2025 | |
| $8.77M | 1.55% | 0.29% | -49.0% | Q4 2024 | |
| $8.67M | 1.53% | 0.33% | New | Q4 2025 | |
| $8.21M | 1.45% | 0.66% | Not reported | Q4 2024 | |
| $7.71M | 1.36% | 2.70% | -3.6% | Q4 2024 | |
| $6.9M | 1.22% | 0.46% | +1.9% | Q4 2024 | |
| $6.68M | 1.18% | 0.33% | New | Q4 2025 | |
| TPTERNTerns Pharmaceuticals, Inc. | $5.53M | 0.98% | 0.12% | New | Q4 2025 |
| $3.74M | 0.66% | 0.17% | -44.2% | Q2 2025 | |
| $3.32M | 0.59% | 0.13% | New | Q4 2025 | |
| $2.59M | 0.46% | 0.08% | -78.0% | Q3 2025 | |
| $2.28M | 0.40% | 0.30% | Not reported | Q1 2025 | |
| $2.09M | 0.37% | 0.23% | New | Q4 2025 | |
| $1.9M | 0.34% | 1.67% | +18.7% | Q3 2025 | |
| $1.29M | 0.23% | Not reported | +92.8% | Q4 2024 | |
| $1.09M | 0.19% | 0.08% | -13.0% | Q3 2025 | |
| $1.05M | 0.19% | 0.78% | Not reported | Q4 2024 | |
| $857K | 0.15% | 1.41% | Not reported | Q4 2024 | |
| $439K | 0.08% | 0.65% | Not reported | Q1 2025 | |
| $157K | 0.03% | 1.17% | Not reported | Q2 2025 | |
| Q3 2025Reported Nov 14, 202537 positions | |||||
| $43.8M | 8.09% | 0.01% | +6.4% | Q1 2025 | |
| $35.9M | 6.63% | 0.01% | New | Q3 2025 | |
| $32.3M | 5.98% | 0.32% | -32.9% | Q4 2024 | |
| $31.9M | 5.90% | 0.02% | +25.9% | Q4 2024 | |
| $28.8M | 5.33% | 0.24% | -19.4% | Q4 2024 | |
| STSLNOSoleno Therapeutics Inc | $28.3M | 5.23% | 0.78% | +2.0% | Q1 2025 |
| $26.3M | 4.86% | 1.56% | -10.6% | Q4 2024 | |
| $25.7M | 4.75% | 0.02% | +14.8% | Q4 2024 | |
| $24.8M | 4.59% | 1.86% | -23.3% | Q1 2025 | |
| $24.8M | 4.59% | 0.38% | -24.9% | Q4 2024 | |
| $23.9M | 4.42% | 0.11% | +52.5% | Q2 2025 | |
| $19.9M | 3.67% | 0.04% | Not reported | Q1 2025 | |
| $18.3M | 3.37% | 0.36% | -2.8% | Q4 2024 | |
| $16.5M | 3.05% | 0.46% | -32.2% | Q4 2024 | |
| $14.3M | 2.65% | 0.62% | +606.2% | Q4 2024 | |
| $13.8M | 2.54% | 0.26% | New | Q3 2025 | |
| $13.7M | 2.54% | 0.50% | New | Q3 2025 | |
| $13.6M | 2.52% | 0.09% | Not reported | Q4 2024 | |
| $13.3M | 2.46% | 1.59% | +67.9% | Q2 2025 | |
| $13.2M | 2.45% | 0.58% | -36.6% | Q1 2025 | |
| ABRNAMAvidity Biosciences, Inc. | $11.5M | 2.12% | 0.18% | New | Q3 2025 |
| $10M | 1.86% | 0.29% | +20.2% | Q4 2024 | |
| $8.76M | 1.62% | 0.30% | +36.5% | Q2 2025 | |
| $8.29M | 1.53% | 3.94% | +2333.9% | Q4 2024 | |
| $8.16M | 1.51% | 0.38% | New | Q3 2025 | |
| $6.53M | 1.21% | 3.89% | -7.7% | Q4 2024 | |
| $5.54M | 1.02% | 0.66% | Not reported | Q4 2024 | |
| CTCDTXCidara Therapeutics, Inc. | $5.11M | 0.94% | 0.18% | New | Q3 2025 |
| $3.52M | 0.65% | 1.34% | Not reported | Q4 2024 | |
| $2.75M | 0.51% | 1.77% | New | Q3 2025 | |
| $1.67M | 0.31% | 0.66% | -29.0% | Q1 2025 | |
| $1.25M | 0.23% | 1.41% | Not reported | Q4 2024 | |
| $993K | 0.18% | Not reported | -9.9% | Q4 2024 | |
| $955K | 0.18% | 0.25% | -18.1% | Q1 2025 | |
| $935K | 0.17% | 1.64% | -2.1% | Q4 2024 | |
| $753K | 0.14% | 0.11% | New | Q3 2025 | |
| $139K | 0.03% | 1.17% | Not reported | Q2 2025 | |
Premium opens every quarter this fund has filed